What is the future of ribavirin therapy for hepatitis C?
What is the future of ribavirin therapy for hepatitis C?
复制标题
DOI：
10.1016/j.antiviral.2014.01.005
复制
发表时间：
2014-04
影响因子：
7.6
通讯作者：
Liang TJ
中科院分区：
文献类型：
--
作者：
Koh C;Liang TJ
With the introduction of direct-acting antiviral (DAA) therapy against hepatitis C virus (HCV) infection, the field is rapidly evolving towards interferon-free regimens with high sustained virologic response (SVR) rates. The ultimate goal of therapy in chronic HCV infection should include an easily dosed all-oral regimen that is highly effective, inexpensive, pan-genotypic, safe and tolerable, with minimal to no resistance. Various investigational DAA regimens are currently under evaluation with and without ribavirin (Rbv). With the projected arrival of improved therapies over the next 5 years, the future role of Rbv comes into question. Despite being plagued by the lack of understanding of its mechanism of action and significant side effects such as anemia, Rbv has been a part of the standard-of-care therapies in chronic HCV infection for more than 10 years. As we look towards the future HCV therapy, Rbv may still have utility in the care of patients infected with HCV because of its low cost and potentially added value in combination with other DAAs. This article forms part of a symposium in Antiviral Research on “Hepatitis C: next steps toward global eradication.”
登录
查看更多内容
影响因子：
13.5
作者：
Ghany, Marc G.;Nelson, David R.;Strader, Doris B.;Thomas, David L.;Seeff, Leonard B.
通讯作者：
Seeff, Leonard B.
影响因子：
158.5
作者：
Lawitz, Eric;Mangia, Alessandra;Gane, Edward J.
通讯作者：
Gane, Edward J.
影响因子：
168.9
作者：
Gane, Edward J.;Roberts, Stuart K.;Smith, Patrick F.
通讯作者：
Smith, Patrick F.
影响因子：
158.5
作者：
Jacobson, Ira M.;McHutchison, John G.;Zeuzem, Stefan
通讯作者：
Zeuzem, Stefan
影响因子：
29.4
作者：
Feld JJ;Lutchman GA;Heller T;Hara K;Pfeiffer JK;Leff RD;Meek C;Rivera M;Ko M;Koh C;Rotman Y;Ghany MG;Haynes-Williams V;Neumann AU;Liang TJ;Hoofnagle JH
通讯作者：
Hoofnagle JH